StockNews.com Initiates Coverage on Nabriva Therapeutics (NASDAQ:NBRV)
StockNews.com Initiates Coverage on Nabriva Therapeutics (NASDAQ:NBRV)
StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) in a note issued to investors on Tuesday. The firm set a "hold" rating on the biotechnology company's stock.
StockNews.com 开始报道的股票 Nabriva Therapeutics（纳斯达克股票代码：NBRV — 获取评级） 在周二发布给投资者的报告中。该公司对这家生物技术公司的股票设定了 “持有” 评级。
Separately, Northland Securities downgraded shares of Nabriva Therapeutics from an "outperform" rating to an "underperform" rating in a report on Friday, January 6th.
另外，Northland Securities在1月6日星期五的一份报告中将Nabriva Therapeutics的股票评级从 “跑赢大盘” 下调至 “表现不佳”。
Nabriva Therapeutics Stock Up 5.7 %
Nabriva Therapeutics股票上涨5.7％
NASDAQ:NBRV opened at $1.49 on Tuesday. The firm has a market cap of $45.65 million, a P/E ratio of -0.08 and a beta of 1.67. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.40 and a current ratio of 2.20. Nabriva Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $14.19. The firm has a 50-day simple moving average of $1.97 and a two-hundred day simple moving average of $3.74.
纳斯达克股票代码：NBRV周二开盘价为1.49美元。该公司的市值为4565万美元，市盈率为-0.08，beta值为1.67。该公司的债务与权益比率为0.02，速动比率为1.40，流动比率为2.20。Nabriva Therapeutics创下五十二周低点1.22美元，五十二周高点为14.19美元。该公司的50天简单移动平均线为1.97美元，两百天简单移动平均线为3.74美元。
Hedge Funds Weigh In On Nabriva Therapeutics
对冲基金对 Nabriva Therapeutics 进行了权衡
An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC increased its holdings in Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) by 102.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 795,938 shares of the biotechnology company's stock after buying an additional 402,144 shares during the quarter. Renaissance Technologies LLC owned 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent reporting period. 0.23% of the stock is currently owned by institutional investors and hedge funds.
一位机构投资者最近提高了其在Nabriva Therapeutics股票中的头寸。Renaissance Technologies LLC在第二季度将其在Nabriva Therapeutics plc（纳斯达克股票代码：NBRV — 获取评级）的持股量增加了102.1％。该基金在本季度又购买了402,144股股票后，拥有这家生物技术公司的795,938股股票。截至最近报告期末，Renaissance Technologies LLC拥有Nabriva Therapeutics0.13％的股份，价值14.5万美元。该股票目前由机构投资者和对冲基金持有。
Nabriva Therapeutics Company Profile
纳布里瓦疗法公司简介
(Get Rating)
（获取评分）
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Nabriva Therapeutics Plc是一家生物制药公司，从事治疗严重感染的新型抗感染药物的研究、开发和商业化。其产品线包括Lefamulin、CONTEPO 和 BC-7013。该公司成立于 2005 年 10 月，总部位于爱尔兰都柏林。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- Don't Miss These 2 Mid-Cap Techs That Broke Out Last Week
- Is Macau a Sinking Ship for Wynn Resorts?
- Why Warner Bros Discovery Is the S&P's Hottest Stock
- Pinterest is the Social Commerce Platform to Watch in 2023
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
- 免费获取 StockNews.com 关于 Nabriva Therapeutics (NBRV) 的研究报告
- 千万不要错过上周爆发的这两家中型股科技公司
- 澳门是永利渡假村的沉船吗？
- 为什么华纳兄弟发现是标准普尔最热门的股票
- Pinterest 是 2023 年值得关注的社交商务平台
- Walgreens Boots Alliance 的收益亏损对投资者有
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Nabriva Therapeutics 每日的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Nabriva Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。